VRCA (Verrica Pharmaceuticals) Long-Term Debt: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRCA Verrica Pharmaceuticals Inc VRCA
45 GF Score
Price $4.99
GF Value $13.24
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Long-Term Debt?

Verrica Pharmaceuticals VRCA -7.25% 45 Long-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates VRCA with a GF Score™ of 45/100 and a GF Value™ of $13.24 (Possible Value Trap). The stock has 2 warning signs investors should review.

Verrica Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2026 was $0.00 Mil.

Verrica Pharmaceuticals's annual Long-Term Debt declined from Dec. 2023 ($42.87 Mil) to Dec. 2024 ($30.98 Mil) and declined from Dec. 2024 ($30.98 Mil) to Dec. 2025 ($0.00 Mil).

Verrica Pharmaceuticals  (NAS:VRCA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Verrica Pharmaceuticals Long-Term Debt Related Terms

Verrica Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals Long-Term Debt Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 42.87 30.98 0.00

Verrica Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.58 21.62 0.00 0.00 0.00
VRCA
45GF Score
Verrica Pharmaceuticals Inc VRCA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Verrica Pharmaceuticals (VRCA) has a Long-Term Debt of $0.00 Mil as of Jun. 2026.
Is Verrica Pharmaceuticals' Long-Term Debt too high?
Verrica Pharmaceuticals' current Long-Term Debt is $0.00 Mil. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Long-Term Debt compare to HRTX and RLYB?
Verrica Pharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Verrica Pharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (VRCA) is currently considered Possible Value Trap. The stock's GF Value™ is $13.24, compared to a current price of $4.99 — trading 62.3% below its estimated fair value. The current Long-Term Debt is $0.00 Mil. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Verrica Pharmaceuticals (VRCA), the current Long-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Verrica Pharmaceuticals (VRCA) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of $4.99 is trading 62.3% below its estimated GF Value™ of $13.24. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for VRCA:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $13.24 vs. price of $4.99 (62.3% below fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the VRCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges 1NE0:Germany
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score

Get the complete analysis for VRCA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price
$13.24
GF Value